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EDITORIAL
Synchronous, Separate, and Similar
Frank C. Detterbeck, MD
This issue of Journal of Thoracic Oncology includes two separate articles that have alot of similarities.1,2 Both address the issue of what to do with patients that present with
the synchronous finding of a primary lung cancer and an additional separate, yet similar
lesion. The article by Finley et al.1 restricts its analysis to patients who were proven to
have synchronous primary lung cancers, whereas the article by Kim et al.2 addresses
patients who have one or more additional ground glass opacities (GGO), and the task of
determining which of these additional lesions is malignant. These articles present a good
opportunity to discuss the topic of how we should think of synchronous, separate nodules
in patients with lung cancer.
The article by Finley et al.1 has several unique features, starting with a new
definition of what should be considered a second primary lung cancer. The widely used
criteria proposed by Martini and Melamed3 in 1975 were empirically derived and have
never been validated. An analysis of data suggests that for metachronous second primary
lung cancers, a 4-year interval is better than the traditional 2-year interval.4,5 Finley et al.
have added definitions to distinguish synchronous tumors, accepting them as second
primary cancers if they are either of a different histologic type or subtype of adenocar-
cinoma. Because most of adenocarcinomas are of mixed subtypes, distinct tumors are
defined by differing proportions of the subtypes. This distinction has been shown to
correlate with genetic differences but has the advantage of being apparent by light
microscopy.6 I believe that this definition will become the new standard, at least for
synchronous tumors. Distinguishing tumors on the basis of genomic signatures remains
costly, available only in research laboratories, is sometimes plagued by conflicting
results,7–9 and, in fact, genetic features correlate quite well with details apparent by light
microscopy.6,10
The study by Finley et al. also used careful staging of the patients to avoid considering
patients as having synchronous second primary cancers if in fact they had evidence of
metastases to distant sites or mediastinal nodes although full details are not explicit. Not all
centers reporting on second primary lung cancers have used such a thorough evaluation,
although this is recommended in the American College of Chest Physicians Lung Cancer
guidelines.4,5
The survival observed in this study (5-year overall survival 55%) is better than
most series of synchronous primary lung cancers (average 5-year survival 30%).11 Is
this because of better patient selection (e.g., more careful staging)? Is this due to a
changing spectrum of disease, with a greater proportion of more indolent tumors (e.g., due
to computed tomography screening, increasing proportion of women or nonsmokers)? Or
is this because we are seeing more of a different kind of non-small cell lung cancer that
has a propensity for multifocal disease?
Unfortunately, there is no information on recurrence patterns. This could shed light
on whether we are dealing with “regular” lung cancers that have been carefully selected,
in which case we should see primarily distant metastases among those patients that
develop recurrent disease. However, if we are dealing with tumors that have a propensity
to multifocal disease in the lungs, we would expect a high proportion of “local recur-
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rences” among those who have a recurrence. Of course, if a
new pulmonary focus of malignancy becomes apparent, it is
difficult to distinguish a local recurrence from a new primary
tumor.
The second article, by Kim et al.,2 reports on patients
with a bronchioloalveolar carcinoma (BAC) who have addi-
tional GGO lesions, realizing that some of these may be (or
may become) synchronous or metachronous foci of malig-
nancy. It seems intuitively easier in the case of a GGO to
think of this as a separate process, as opposed to a metastasis.
Consistent with this sentiment, the authors do not dwell on
describing how metastases are excluded (other than using the
classic criteria of Martini and Melamed). BAC was found in
25% of the additional GGO lesions that were biopsied. These
results are not limited only to BAC, as evidenced by another
study from this same group,12 involving patients with a
dominant lung cancer who have additional GGO. Lesions that
were lobulated, and especially, lesions larger than 10 mm had
a relatively high chance of being recognized as additional foci
of malignancy (45 and 67%, respectively).
But how should we think about these additional foci of
malignancy? Are they synchronous second primary cancers
that are the same as in the first article by Finley et al (which
were almost all solid lesions without a significant GGO
component)1? Or is there something different about these
second primary cancers that arise from a GGO? It should be
noted that on average there were three GGOs per patient—so
are many of these patients exhibiting multiple primary can-
cers? Are we dealing with a different type of tumor that has
a propensity to develop multifocal disease in the lungs?
Multifocal disease is well recognized for BAC,13–15 but the
large majority of both the dominant initial tumor and the
secondary cancers were adenocarcinomas and not BAC.2
However, the distinction between adenocarcinoma and BAC
is becoming increasingly indistinct, and in the near future, the
official pathologic nomenclature may no longer include BAC
(instead, pure BAC will be referred to as adenocarcinoma in
situ).16 The fact that some GGOs eventually grow, develop a
solid component, and are classified histologically at this point as
an adenocarcinoma has long been recognized.14,17,18 Further-
more, many clinical and pathologic studies have suggested that
BAC may be a precursor to invasive adenocarcinoma.14,15,19–21
If we assume that a form of lung cancer exists that is
prone to multifocal disease, what etiologic factors play a
role? Is this a manifestation of field cancerization? Is this due
to infection, perhaps by an unknown oncogenic virus? Or is
this due to an alteration in the host, for example resulting in
a favorable microenvironment in the lung or in altered im-
mune recognition?
The new International Association for the Study of
Lung Cancer (IASLC) staging system does not make it clear
how to think about these patients. The new staging system
has defined nomenclature for additional nodules of the same
histologic type,22 but in fact most of patients that have been
defined as having synchronous primary cancers have had
tumors of the same histologic type. Synchronous second
primary tumors were excluded from the IASLC analysis, but
the definition of this was left to each center that submitted
data. The new staging system has viewed these additional
nodules primarily as isolated pulmonary metastases, but, in
fact, the survival is much better that for isolated metastases at
any other site (1-year survival 45% versus 23% for cM1a-
contralateral nodule versus cM1b-single site).23 Hence, what
is the nature of these “additional nodules”? This confusion is
apparent in the discussion by Finley et al., who argue that
their data on synchronous primaries support the IASLC
reclassification of additional nodules.1
Of note, the IASLC analysis of additional nodules was
dominated by data from Asia (just like the origin of the
patients in the article by Kim et al.).2 Is there a subset of
patients in Asia that are fundamentally different, with a
predisposition to multifocal disease, usually arising from a
GGO? Most of articles discussing multifocal cancers or
GGOs have come from Asia. Is this due to a heightened
awareness or recognition of this phenomenon? Or is this due
to a more widespread use of computed tomography as a
screening tool for lung cancer?
Are the patients considered in the articles by Finley et
al. and Kim et al. the same, with only a slight difference in the
point during the natural history of the disease at which they
are studied? Or is there an inherent biologic difference in the
type of patients and tumors between these studies? Are solid,
spiculated tumors biologically different than those that appear
radiographically as a GGO? Are tumors in North America
biologically different than tumors in Asia?
Although clear answers to these questions are not
available, we have to try to draw what conclusions we can
from the data available. First, I believe that the system of
defining synchronous primary lung cancers in the article by
Finley et al. should become the new standard. I also believe
that we should adopt the ACCP definition of metachronous
lung cancers,4,5 rather than continue to rely on the criteria of
Martini and Melamed3) that were derived empirically 35
years ago.
Second, we should be carefully, thoughtfully aggres-
sive in treating patients that may have synchronous primary
lung cancers. I would define this as patients who have solid
masses that fit the appearance of traditional lung cancers (i.e.,
spiculated). These patients should undergo very careful in-
vestigation for distant or mediastinal metastases, but if this is
negative, they should undergo definitive treatment with cur-
ative intent. The second lesion should be thought of as a
pulmonary metastasis only if the histologic type and subtype
is exactly the same and there are distant or mediastinal
metastases.
Third, we certainly should be aggressive in treating the
primary tumor in patients that harbor an additional GGO. It is
reasonable to follow these additional lesions if they are pure
GGO and less than 10 mm in diameter. If the additional focus
exceeds 10 mm or develops a solid component, it should be
biopsied or resected. The size cutpoint that should trigger
intervention has been arbitrary, but the study by Kim et al.
provides reasonable data to justify 10 mm.12
Fourth, I believe that we need to maintain an open mind
about the nature of multiple foci of pulmonary malignancy,
especially when these have a ground glass component. This
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may be a different kind of lung cancer that has a propensity
for multifocal involvement. There are some data to suggest
that these tumors have a decreased propensity to metasta-
size,14,19,24,25 making them good candidates for parenchymal
sparing local therapy with curative intent. However, research
is needed to substantiate or refute this impression.
Finally, we need to develop a set of criteria to distin-
guish a synchronous second primary cancer from an isolated
pulmonary metastasis, an “additional nodule” and multifocal
disease. A definition would at least allow us to assemble
some data to guide this process. We need this both to define
how to approach the patients addressed in the two articles that
are the focus of this editorial and prospectively to understand
the additional nodule category of the new IASLC staging
system.
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